M.D. Anderson Holds First Cancer Meeting in Spanish
HOUSTON--Spanish-speaking oncologists from around the world stopped off in Houston on their way home from the ASCO meeting to learn more about state-of-the-art cancer care--in their own language.
HOUSTON--Spanish-speaking oncologists from around the world stoppedoff in Houston on their way home from the ASCO meeting to learnmore about state-of-the-art cancer care--in their own language.
The University of Texas M.D. Anderson Cancer Center sponsoredthe 2-day Conferencia Internacional de Oncologist Medica, thefirst ever to be presented exclusively in Spanish at the cancercenter.
"M.D. Anderson is probably the only center in the countrythat could put together such a program in Spanish. At least onephysician or researcher in each of our major services speaks fluentSpanish, and these faculty are on the conference program,"said Dr. Richard Pazdur, assistant vice president of academicaffairs and a conference organizer.
About 5% of M.D. Anderson's patients come from other countriesand most of them speak Spanish. To assist these patients, theCenter has established the International Patient Center, a patientfamily hotel where multilingual staff serve as advocates for patientsfar from home.
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer
Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.
